Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

EB01

Other · developed by Edesa Biotech

Phase 2 Most advanced trial (none active)

EDSA Developer

1 Registered trials

What is EB01?

EB01 is a topical cream formulation tested at 0.2%, 1.0% and 2.0% concentrations against a vehicle cream with no active agent. It is studied in allergic contact dermatitis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Other
Therapy area: Dermatology
Developer: Edesa Biotech Inc. (EDSA)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03680131	Phase 2	Allergic Contact Dermatitis	Completed	EDSA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Allergic Contact Dermatitis

More from Edesa Biotech

Paridiprubart Phase 2

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the EDSA page.

Follow EDSA, the company behind EB01

See EDSA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

EDSA catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z